Cardio Diagnostics Holdings Inc. Common stock (CDIO)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, the shares were $1.75, with a FairStock market capitalization of $5.2 million. FairStock shows a P/E of -0.60 and a P/B of 0.70; that seems cheap against book value, but the business is losing money badly. FairStock calculates return on equity at -75.44% and return on capital employed at -44.06%, so book value is being consumed, not compounded. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was just $5,360 and net income was -$1.5 million, or diluted EPS -$0.51. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $2,680 and net loss was $1.8 million. Compare fiscal Q2 2025, when revenue was $7,475 and net loss was $1.7 million; the latest reported quarter's revenue actually fell year over year. Full-year filed figures show FY2025 revenue of $14,825 and a net loss of $6.5 million, after FY2024 revenue of $34,890 and a net loss of $8.4 million. The company has lost money in each of the last four years, which is why the computed Lynch category is none. Free cash flow is -$6.1 million over the trailing twelve months, a FCF yield of -117.9% on the FairStock market cap. The Altman Z-Score of 0.73 signals financial stress, though debt to equity is low at 0.05. Piotroski is 5/9. With only 15 employees and no history of profits, there is no obvious moat. Graham would ask for tangible value and earnings stability; I see neither. This is a speculative early-stage story, not a value investment, unless revenue scales and cash losses narrow materially.

In plain English: Cardio Diagnostics develops blood tests that use genetics to help assess heart disease risk. The business is very small and losing money: in the quarter ended June 30, 2026, it reported revenue of $5,360 and a net loss of $1.5 million. At $1.75 a share on October 13, 2026, the price looks low compared with the value of its reported assets, but the company burns cash and has not yet shown it can earn a profit.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer